Isaac Tunnell
Medical · Las Vegas, NVNPI 1164670634
Payments from drug & device makers
Across 636 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$2K
- Scilex Pharmaceuticals Inc.$1K
- AbbVie$1K
- Biohaven Pharmaceuticals, Inc.$885
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$834
- Pfizer$709
- plus $3K from 23 others
What the payments were for
- Consulting fees$8008%
- Food & beverage$9,68092%
- Education$140%
- Gifts$00%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 132 | $2,031 |
| Scilex Pharmaceuticals Inc. | 107 | $1,469 |
| AbbVie | 72 | $1,225 |
| Biohaven Pharmaceuticals, Inc. | 12 | $885 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 51 | $834 |
| Pfizer | 42 | $709 |
| Indivior Inc. | 21 | $476 |
| Braeburn Inc. | 16 | $311 |
| Redhill Biopharma Inc. | 19 | $293 |
| Almatica Pharma LLC | 46 | $278 |
| Idorsia Pharmaceuticals US Inc | 14 | $239 |
| Orexo US, Inc. | 10 | $211 |
| Biodelivery Sciences International, Inc. | 28 | $180 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $176 |
| Axsome Therapeutics, Inc. | 8 | $173 |
| Lundbeck LLC | 6 | $157 |
| Forte Bio-pharma LLC | 5 | $125 |
| IBSA Pharma Inc. | 5 | $110 |
| Arbor Pharmaceuticals, Inc. | 5 | $108 |
| Protega Pharmaceutials Inc | 5 | $94 |
| Abbott | 4 | $84 |
| Lilly USA, LLC | 5 | $72 |
| Azurity Pharmaceuticals, Inc. | 4 | $65 |
| Nevro Corp. | 2 | $63 |
| GRT US Holding, Inc. | 3 | $50 |
| Boston Scientific | 1 | $24 |
| Averitas Pharma Inc. | 1 | $20 |
| USWM, LLC | 1 | $15 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$800
How this compares
$10,494 in reported general payments places this provider in the 95th percentile of 250 medical providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 90 | $57,483 |
| Nucynta ErTapentadol Hcl | 28 | $42,473 |
| SprixKetorolac Tromethamine | 12 | $30,952 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 135 | $24,079 |
| Tramadol Hcl ErTramadol Hcl | 301 | $17,767 |
| Hysingla ErHydrocodone Bitartrate | 24 | $16,692 |
| NucyntaTapentadol Hcl | 25 | $15,839 |
| HorizantGabapentin Enacarbil | 15 | $15,194 |
| Morphine Sulfate ErMorphine Sulfate | 384 | $12,567 |
| DayvigoLemborexant | 30 | $10,562 |
| Morphine Sulfate | 372 | $9,873 |
| ButransBuprenorphine | 20 | $9,827 |
| ZtlidoLidocaine | 16 | $8,681 |
| Buprenorphine | 43 | $8,017 |
| Gabapentin | 440 | $7,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Nucynta | $2,031 | $115,795143 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $108 | $15,19415 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $1,469 | $8,68116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 medical providers in Nevada.
Other medical in Las Vegas
- John NotabartoloLas Vegas$284K
- Rachel BowersLas Vegas$29K
- Spencer MeierLas Vegas$24K
- Megan WieselLas Vegas$19K
- Tai PhamLas Vegas$16K
- Eric HilmesLas Vegas$15K
- Wardon OjedapoLas Vegas$12K
- Melchor GochiocoLas Vegas$11K
- Keesha KaplanLas Vegas$11K
- Adelbert WadsworthLas Vegas$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.